摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-甲氧基苯基)-2-苯基喹啉-4-甲酰胺 | 88067-77-0

中文名称
N-(4-甲氧基苯基)-2-苯基喹啉-4-甲酰胺
中文别名
——
英文名称
N-(4-methoxyphenyl)-2-phenylquinoline-4-carboxamide
英文别名
——
N-(4-甲氧基苯基)-2-苯基喹啉-4-甲酰胺化学式
CAS
88067-77-0
化学式
C23H18N2O2
mdl
MFCD00249836
分子量
354.408
InChiKey
AFAFDMOIWWTYNC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    502.2±50.0 °C(Predicted)
  • 密度:
    1.243±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    4.7
  • 重原子数:
    27
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.04
  • 拓扑面积:
    51.2
  • 氢给体数:
    1
  • 氢受体数:
    3

SDS

SDS:3481e6b94e39bb8ed5d547200f408e4b
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N-(4-甲氧基苯基)-2-苯基喹啉-4-甲酰胺三溴化硼 作用下, 以 二氯甲烷 为溶剂, 反应 0.75h, 以83%的产率得到N-(4-hydroxyphenyl)-2-phenylquinoline-4-carboxamide
    参考文献:
    名称:
    Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates
    摘要:
    药物及药物候选物代谢物的鉴定和定量通常使用液相色谱-质谱联用技术 (LC-MS) 进行。最佳实践是生成以代谢物与内标的标准曲线。然而,为了避免代谢物合成的困难,有时会使用底物来准备标准曲线,假设底物和代谢物的信号是等效的。我们使用一系列非常相似的化合物,这些化合物经历共同的代谢反应,测试了这一假设所带来的误差,采用了传统流动电喷雾电离 LC-MS 和低流量捕获喷雾电离 (CSI) LC-MS 方法。文中展示了四种不同转化类型(O-去甲基化、N-去甲基化、芳香族羟基化和苄基羟基化)的标准曲线差异。结果表明,在20种底物-代谢物组合中的18种情况下,两种方法中底物和代谢物的信号在统计上是显著不同的。标准曲线的斜率比率最高可变化4倍,但CSI方法的变化略小。
    DOI:
    10.1124/dmd.111.040865
  • 作为产物:
    描述:
    2-苯基-4-喹啉羧酸吡啶氯化亚砜 作用下, 以 甲苯 为溶剂, 反应 6.0h, 生成 N-(4-甲氧基苯基)-2-苯基喹啉-4-甲酰胺
    参考文献:
    名称:
    喹啉基STAT3小分子抑制剂的设计,合成与评价
    摘要:
    由于STAT3已被确认为抗癌靶标,因此已证明其抑制剂具有治疗人类癌症的治疗前景。为了鉴定新型和选择性的STAT3抑制剂,进行了基于STAT3 SH2结构域的虚拟筛选,以及一个小分子2-苯基喹啉-4-羧酸(5a),其抑制常数K i发现STAT3的值17.53μM。在此基础上,合成了5a的衍生物,包括酯,酰胺和二聚体。使用人乳腺癌细胞系MDA-MB-468和MCF-7测定了衍生物的生物活性和抑制选择性。在这些衍生物中,5c和9b表现出最强的抑制活性和良好的选择性,并且还抑制了MDA-MB-468细胞的STAT3蛋白水平。结果证明了虚拟筛选技术在铅发现中的成功应用。化合物9b可能是抗肿瘤药进一步开发的有效STAT3抑制剂。
    DOI:
    10.2174/1570180811310050009
点击查看最新优质反应信息

文献信息

  • Design, synthesis and biological evaluation of 2-phenylquinoline-4-carboxamide derivatives as a new class of tubulin polymerization inhibitors
    作者:Li Zhu、Kaixiu Luo、Ke Li、Yi Jin、Jun Lin
    DOI:10.1016/j.bmc.2017.09.004
    日期:2017.11
    inhibitory effect on tubulin polymerization. In addition, immunofluorescence and flow cytometry analysis revealed that selected compounds caused disruption of the mitotic spindle assembly and G2/M phase arrest of the cell cycle, which correlated with proliferation inhibitory activity. Molecular docking analysis demonstrated the interaction of 7b at the colchicine binding site of tubulin. These results indicate
    合成,表征和评估了一系列新的2-苯基喹啉-4-羧酰胺衍生物对五种癌细胞系(Hela,SK-OV-3,HCT116,A549和MDA-MB-468)和正常人的抗增殖活性胎儿肺成纤维细胞系,MRC-5。其中,化合物7b在体外显示出对SK-OV-3和HCT116细胞系的有效细胞毒活性,IC 50值分别为0.5和0.2μM。通常,抗增殖活性与秋水仙碱结合位点的结合特性和对微管蛋白聚合的抑制作用有关。此外,免疫荧光和流式细胞仪分析表明,选定的化合物导致有丝分裂纺锤体装配和G 2的破坏细胞周期的/ M期停滞,与增殖抑制活性有关。分子对接分析表明7b在微管蛋白的秋水仙碱结合位点相互作用。这些结果表明这些化合物是用于有效治疗癌症的微管蛋白聚合的有希望的抑制剂。
  • Cinchophen Analogues as Potential CNS Agents
    作者:A. Kar
    DOI:10.1002/jps.2600720931
    日期:1983.9
    Several amides of cinchophen were prepared and evaluated as CNS agents. Compounds III, VII, XII, XIII, and XIV exhibited analgesic activity while I, III, and XIV acted as CNS depressants.
    制备了几种噻吩甲酰胺,并作为中枢神经系统药物进行了评估。化合物III,VII,XII,XIII和XIV表现出止痛活性,而化合物I,III和XIV充当中枢神经系统抑制剂。
  • Comparative Study of the Affinity and Metabolism of Type I and Type II Binding Quinoline Carboxamide Analogues by Cytochrome P450 3A4
    作者:Upendra P. Dahal、Carolyn Joswig-Jones、Jeffrey P. Jones
    DOI:10.1021/jm201207h
    日期:2012.1.12
    Compounds that coordinate to the heme-iron of cytochrome P450 (CYP) enzymes are assumed to increase metabolic stability. However, recently we observed that the type II binding quinoline carboxamide (QCA) compounds were metabolically less stable. To test if the higher intrinsic clearance of type II binding compounds relative to type I binding compounds is general for other metabolic transformations, we synthesized a library of QCA compounds that could undergo N-dealkylation, O-dealkylation, benzylic hydroxylation, and aromatic hydroxylation. The results demonstrated that type II binding QCA analogues were metabolically less stable (2- to 12-fold) at subsaturating concentration compared to type I binding counterparts for all the transformations. When the rates of different metabolic transformations between type I and type II binding compounds were compared, they were found to be in the order of N-demethylation > benzylic hydroxylation > O-demethylation > aromatic hydroxylation. Finally, for the QCA analogues with aza-heteroaromatic rings, we did not detect metabolism in aza-aromatic rings (pyridine, pyrazine, pyrimidine), indicating that electronegativity of the nitrogen can change regioselectivity in CYP metabolism.
  • Design, Synthesis and Evaluation of Quinoline-based Small Molecule Inhibitor of STAT3
    作者:Zhi-Bing Shi、Lei Zhang、Zheng-Yang Bin、Xiang-Rong Cao、Zhu-Nan Gong、Jian-Xin Li
    DOI:10.2174/1570180811310050009
    日期:2013.4.1
    As STAT3 has been validated as an anticancer target, its inhibitors have been shown to possess therapeutic promise for the treatment of human cancers. To identify novel and selective STAT3 inhibitors, a virtual screening based on the STAT3 SH2 domain was performed and a small molecule, 2-phenylquinoline-4-carboxylic acid (5a), with an inhibition constant Ki value of 17.53 μM to STAT3 was discovered
    由于STAT3已被确认为抗癌靶标,因此已证明其抑制剂具有治疗人类癌症的治疗前景。为了鉴定新型和选择性的STAT3抑制剂,进行了基于STAT3 SH2结构域的虚拟筛选,以及一个小分子2-苯基喹啉-4-羧酸(5a),其抑制常数K i发现STAT3的值17.53μM。在此基础上,合成了5a的衍生物,包括酯,酰胺和二聚体。使用人乳腺癌细胞系MDA-MB-468和MCF-7测定了衍生物的生物活性和抑制选择性。在这些衍生物中,5c和9b表现出最强的抑制活性和良好的选择性,并且还抑制了MDA-MB-468细胞的STAT3蛋白水平。结果证明了虚拟筛选技术在铅发现中的成功应用。化合物9b可能是抗肿瘤药进一步开发的有效STAT3抑制剂。
  • Small Molecule Quantification by Liquid Chromatography-Mass Spectrometry for Metabolites of Drugs and Drug Candidates
    作者:Upendra P. Dahal、Jeffrey P. Jones、John A. Davis、Dan A. Rock
    DOI:10.1124/dmd.111.040865
    日期:2011.12
    Identification and quantification of the metabolites of drugs and drug candidates are routinely performed using liquid chromatography-mass spectrometry (LC-MS). The best practice is to generate a standard curve with the metabolite versus the internal standard. However, to avoid the difficulties in metabolite synthesis, standard curves are sometimes prepared using the substrate, assuming that the signal for substrate and the metabolite will be equivalent. We have tested the errors associated with this assumption using a series of very similar compounds that undergo common metabolic reactions using both conventional flow electrospray ionization LC-MS and low-flow captive spray ionization (CSI) LC-MS. The differences in standard curves for four different types of transformations (O-demethylation, N-demethylation, aromatic hydroxylation, and benzylic hydroxylation) are presented. The results demonstrate that the signals of the substrates compared with those of the metabolites are statistically different in 18 of the 20 substrate-metabolite combinations for both methods. The ratio of the slopes of the standard curves varied up to 4-fold but was slightly less for the CSI method.
    药物及药物候选物代谢物的鉴定和定量通常使用液相色谱-质谱联用技术 (LC-MS) 进行。最佳实践是生成以代谢物与内标的标准曲线。然而,为了避免代谢物合成的困难,有时会使用底物来准备标准曲线,假设底物和代谢物的信号是等效的。我们使用一系列非常相似的化合物,这些化合物经历共同的代谢反应,测试了这一假设所带来的误差,采用了传统流动电喷雾电离 LC-MS 和低流量捕获喷雾电离 (CSI) LC-MS 方法。文中展示了四种不同转化类型(O-去甲基化、N-去甲基化、芳香族羟基化和苄基羟基化)的标准曲线差异。结果表明,在20种底物-代谢物组合中的18种情况下,两种方法中底物和代谢物的信号在统计上是显著不同的。标准曲线的斜率比率最高可变化4倍,但CSI方法的变化略小。
查看更多